Zealand Pharma A/S (OTCMKTS:ZLDPF) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) have been assigned a consensus recommendation of “Hold” from the nine research firms that are currently covering the stock, MarketBeat.com reports. Eight investment analysts have rated the stock with a hold rating and one has issued a strong buy rating on the company.

Several analysts have weighed in on the company. Wolfe Research lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Zealand Pharma A/S in a research note on Thursday, June 4th. Jefferies Financial Group cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Finally, Berenberg Bank downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Wednesday, June 17th.

Zealand Pharma A/S Stock Performance

ZLDPF opened at $50.50 on Thursday. The stock has a market cap of $3.61 billion, a P/E ratio of 3.75 and a beta of 0.88. The company has a debt-to-equity ratio of 0.02, a current ratio of 37.17 and a quick ratio of 37.17. The stock’s 50 day simple moving average is $45.44 and its 200 day simple moving average is $49.76. Zealand Pharma A/S has a 1-year low of $35.93 and a 1-year high of $83.12.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark?based biopharmaceutical company specializing in the discovery, design and development of peptide?based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.